List of works - Sergei D. Rybalkin

A conjugate of decyltriphenylphosphonium with plastoquinone can carry cyclic adenosine monophosphate, but not cyclic guanosine monophosphate, across artificial and natural membranes

scientific article published on 13 October 2017

Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling

scientific journal article

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets.

scientific article published in August 2011

Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes

scientific article

Cyclic GMP phosphodiesterases and regulation of smooth muscle function

scientific article

Cyclic nucleotide analogs as probes of signaling pathways.

scientific article

Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation

scientific article

Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy.

scientific article published on 29 August 2013

Enzyme assays for cGMP hydrolyzing phosphodiesterases

scientific article published on January 2013

Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.

scientific article published in July 2003

Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis

scientific article published on 23 March 2016

Molecular targets for PDE inhibitor-mediated improvement of cardiac dysfunction in the mdx mouse?

scientific article published in August 2011

Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms

scientific article published on 19 January 2010

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

scientific journal article

PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects

article

Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig.

scientific article published on 21 September 2005

Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells

scientific article published on 26 November 2001

Reply to Kass and Takimoto: Cardiac hypertrophy without cGKI and PDE5 in cardiac myocytes

scientific article published on 24 May 2010

Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy

scientific article

Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.

scientific article

Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation

scientific article published on 10 May 2021

Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond.

scientific article

cGMP kinase I, cardiac hypertrophy and PDE inhibition.

scientific article published in August 2011

List of works by Sergei D. Rybalkin

A conjugate of decyltriphenylphosphonium with plastoquinone can carry cyclic adenosine monophosphate, but not cyclic guanosine monophosphate, across artificial and natural membranes

Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets.

Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes

Cyclic GMP phosphodiesterases and regulation of smooth muscle function

Cyclic nucleotide analogs as probes of signaling pathways.

Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation

Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy.

Enzyme assays for cGMP hydrolyzing phosphodiesterases

Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.

Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis

Molecular targets for PDE inhibitor-mediated improvement of cardiac dysfunction in the mdx mouse?

Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects

Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig.

Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells

Reply to Kass and Takimoto: Cardiac hypertrophy without cGKI and PDE5 in cardiac myocytes

Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy

Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis.

Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation

Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond.

cGMP kinase I, cardiac hypertrophy and PDE inhibition.